Solaris Estates Marks Second Year of Platform Expansion with Broadened National Project Pipeline

Solaris Estates LLC, a national multifamily real estate operating company with more than two decades of experience in real assets, announced continued momentum as it marks the second year of expanding ...

Stromasys Launches Charon-PAR 4.0 – A Major Advancement to Its PA-RISC Emulator

Stromasys announces a major milestone for its PA-RISC emulation technology, releasing a new version designed to boost ...
PharmiWeb

Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once ...

Olanzapine long-acting injectable suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation 1If approved, TEV-'749 could help address a ...

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly ...

Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address ...

Teva Pharmaceutical Industries Ltd: U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV ...

Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address ...